ClinicalTrials.gov
ClinicalTrials.gov Menu

Pertussis Immunization Programs in Low Income Countries - Ivory Coast (PERILIC-IC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03388034
Recruitment Status : Not yet recruiting
First Posted : January 2, 2018
Last Update Posted : January 2, 2018
Sponsor:
Collaborators:
Institut Pasteur de Côte d'Ivoire
Sanofi Pasteur, a Sanofi Company
Information provided by (Responsible Party):
Institut Pasteur

Brief Summary:

Due to waning of infectious as well as vaccine immunity and lack of vaccination boosters, a large number of adolescents and adults are no longer immunized against Bordetella pertussis, the agent of whooping cough and consequently may contract whooping cough. Furthermore, these populations represent a reservoir of the infectious agent from which the dissemination to non-immune infants is possible, causing severe illness, or even death, in this age group.

Few studies have been carried out on whooping cough in developing countries (incidence, contaminator's age, etc.) and, specifically, none have assessed the duration of protection induced by the whole cell pertussis (wP) vaccine mainly presently used in these countries.

However, data on the duration of vaccine induced protection are essential to determine i) the usefulness of vaccine boosters and ii) the target age group for these boosters.

The aims of the present study are:

  • To evaluate the proportion of confirmed pertussis cases in infants presenting whooping cough syndrome (WP1a)
  • To evaluate the proportion of confirmed pertussis cases or healthy carriers among contact cases
  • To determine origin of the infant's contamination (WP1b)
  • To determine the duration of protection induced by the wP vaccines used in contact cases and the child population aged 3 to 15 yo (WP1b and WP2)
  • To bring new scientific evidences documenting the potential need for initiating boosters (WP1b and WP2)
  • To allow a comparison of the results with those obtained using the same methodology for the acellular pertussis vaccine and/or in other contexts. Potential implications for the use of pertussis vaccines in low and moderate income countries.
  • To increase local capabilities by the transfer of materials and expertise that will make the diagnosis of pertussis possible in the centres of reference and strengthen a pertussis monitoring network in the implicated countries.
  • To improve children's health through a better match of the vaccination schedule according to the reality of the situation.

Condition or disease Intervention/treatment
Bordetella Pertussis, Whooping Cough Procedure: Nasopharyngeal sampling Procedure: Blood Sampling

  Show Detailed Description

Study Type : Observational
Estimated Enrollment : 1150 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pertussis Immunization Programs in Low Income Countries - Ivory Coast
Estimated Study Start Date : January 2018
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
Index case (WP1a)

Infant under 6 months old with clinical signs of whooping cough syndrome.

Nasopharyngeal sampling:

A nasopharyngeal sample collected from each nostril by swabbing

Procedure: Nasopharyngeal sampling
A nasopharyngeal sample collected from each nostril by swabbing
Control case (WP1b)

Contact cases of infant with a positive diagnosis for whooping cough.

Nasopharyngeal sampling:

A nasopharyngeal sample collected from each nostril by swabbing

Blood sampling:

A blood sample collected by fingerprick

Procedure: Nasopharyngeal sampling
A nasopharyngeal sample collected from each nostril by swabbing
Procedure: Blood Sampling
Blood sample by the tip of a finger (fingerprick)
Seroepidemiological cohort (WP2)

Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis

Blood sampling:

A blood sample collected by fingerprick

Procedure: Blood Sampling
Blood sample by the tip of a finger (fingerprick)



Primary Outcome Measures :
  1. Proportion of biologically confirmed cases of pertussis in patients under 6 months old admitted into hospital with clinical signs corresponding to whooping cough syndrome. [ Time Frame: December 2019 ]
    Primary Outcome of Cohort 1 (WP1a)

  2. Identification of the contaminator of the index case [ Time Frame: December 2019 ]
    Primary Outcome of Cohort 2 (WP1b)

  3. Estimation of the protection period induced by the primo-vaccination in children between 3 and 15 yo [ Time Frame: December 2019 ]
    Primary Outcome of Cohort 3 (WP2)


Secondary Outcome Measures :
  1. Estimation of the relative risk of the disease occurring in the contact patients based on their immunization status and age groups [ Time Frame: June 2020 ]

Biospecimen Retention:   Samples Without DNA
Nasopharyngeal sample; Blood sample


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Cohort 1 (WP1a): Infants under 6 months old coming to hospital with clinical signs of whooping cough syndrome.

Cohort 2 (WP1b): Contact cases of confirmed infants included in the WP1a module Cohort 3 (WP2): Children from 3 to 15 years old included, without underlying illness, with complete pertussis primo-vaccination

Criteria

Inclusion Criteria (Cohort 1):

  • Infants under 6 months old
  • Presenting clinical signs of a whooping cough syndrome
  • Written consent obtained from a parent/guardian of the child

Inclusion Criteria (Cohort 2):

  • People in regular and prolonged contact (>3h per day) with the index case for at least 15 days before the signs of whooping cough occurred in the infected child, living (or not) in the same household.
  • For the adults, written consent obtained.
  • For minors under 7 yo: written consent obtained from a parent/guardian.
  • For minors over 7 yo: written consent obtained from parent/guardian and oral assent obtained from the child.

Inclusion Criteria (Cohort 3):

  • Child aged between 3 and 15 yo
  • Up to date first pertussis vaccination (vaccination booklet or official register)
  • Last pertussis vaccination done more than one year before inclusion
  • For minors under 7 yo: written consent obtained from parent/guardian.
  • For minors over 7 yo: written consent obtained from parent/guardian and oral assent obtained from the child.

Exclusion Criteria (Cohort 3):

  • Pertussis vaccination done more than one year before inclusion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03388034


Contacts
Contact: Fabien TAIEB, MD, MSc, MPH +33(0)140613456 fabien.taieb@pasteur.fr
Contact: Mohand AIT AHMED, Clinical PM +33(0)144389302 mohand.ait-ahmed@pasteur.fr

Locations
Côte D'Ivoire
Centre de Santé Urbain à base Communautaire (CSU-Com) d'Angré Not yet recruiting
Abidjan, Côte D'Ivoire
Contact: Flavie ACHI, MD         
Principal Investigator: Flavie ACHI, MD         
CHU d'Angré Not yet recruiting
Abidjan, Côte D'Ivoire
Contact: Flore AMON-TANO-DICK, MD         
Principal Investigator: Flore AMON-TANO-DICK, MD         
Hôpital Général de Port-Bouët Not yet recruiting
Abidjan, Côte D'Ivoire
Contact: Mariame DRAME-DEME, MD         
Principal Investigator: Mariame DRAME-DEME, MD         
Hôpital Général de Yopougon Attié
Abidjan, Côte D'Ivoire
Institut Pasteur de Côte d'Ivoire Not yet recruiting
Abidjan, Côte D'Ivoire
Contact: Man-Koumba SOUMAHORO, PhD    + 225 03 53 04 36    mksoumahoro@pasteur.ci   
Sponsors and Collaborators
Institut Pasteur
Institut Pasteur de Côte d'Ivoire
Sanofi Pasteur, a Sanofi Company
Investigators
Principal Investigator: Fabien TAIEB, MD, MSc, MPH Institut Pasteur
Principal Investigator: Man-Koumba SOUMAHORO, PhD Institut Pasteur de Côte d'Ivoire
Study Chair: Nicole GUISO, PhD Institut Pasteur

Additional Information:
Publications of Results:
Other Publications:
Responsible Party: Institut Pasteur
ClinicalTrials.gov Identifier: NCT03388034     History of Changes
Other Study ID Numbers: 2017-056
First Posted: January 2, 2018    Key Record Dates
Last Update Posted: January 2, 2018
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Whooping Cough
Bordetella Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Respiratory Tract Infections
Infection
Respiratory Tract Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs